about
Digestive toxicity of low-dose aspirin: an underestimated and unresolved problemShould Helicobacter pylori infection be tested and eradicated in patients treated or about to be treated with aspirin or nonsteroidal anti-inflammatory drugs?Gastrointestinal complications of nonsteroidal anti-inflammatory drugs and low-dose aspirinEpidemiology of gastroduodenal complications associated with nonsteroidal anti-inflammatory drug useGastrointestinal complications related to NSAIDsDiagnosis of hepatocellular carcinoma in cirrhotic patients: a proof-of-concept study using serum micro-Raman spectroscopy.Jejunoileal Crohn's disease: a case-control study.[Partial regression of Barret esophagus with high grade dysplasia and adenocarcinoma after photocoagulation and endocurietherapy under antisecretory treatment]Developing and understanding biofluid vibrational spectroscopy: a critical review.Mesenteric panniculitis: review of consecutive abdominal MDCT examinations with a matched-pair analysis.Impact of Visceral Obesity on Microvascular Invasion in Hepatocellular Carcinoma.Biofluid infrared spectro-diagnostics: pre-analytical considerations for clinical applications.[Primary leiomyosarcoma of the liver 37 years after successful treatment of hereditary retinoblastoma]Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.Treatment of mild chronic hepatitis C with interferon alpha-2b: results of a multi-centre randomized study in 80 patients.Noninvasive assessment of hepatic fibrosis in patients with chronic hepatitis C using serum Fourier transform infrared spectroscopy.Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases.Bile analysis using high-throughput FTIR spectroscopy for the diagnosis of malignant biliary strictures: a pilot study in 57 patients.Profiling serologic biomarkers in cirrhotic patients via high-throughput Fourier transform infrared spectroscopy: toward a new diagnostic tool of hepatocellular carcinoma.Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis.[Reversible adrenal insufficiency after interferon-alpha therapy for chronic hepatitis C].Proximal predominance of small bowel injury associated with uncoated low-dose aspirin therapy: a video capsule study in chronic users.[Glimepiride-induced cute cholestatic hepatitis].[Hepatocellular carcinoma invading the right atrium: clinical, echographic and angiographic study]Gastric tuberculous abscesses.Central nervous system action of thyrotropin-releasing hormone to increase gastric mucosal blood flow in the rat.Infliximab-induced hepatitis: absence of cross-toxicity with etanercept.Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C.Late autoimmune hepatitis after hepatitis C therapy.Is there any relationship between pernicious anemia and iron deficiency?[Cell proliferation, dysplasia, hyperplasia and carcinogenesis]Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C.Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis: A Preliminary Study[Cardiopexy using the hepatic ligament in the treatment of gastroesophageal reflux. Apropos of 200 cases][Epidemiology and treatment of gastroduodenal lesions caused by non-steroidal anti-inflammatory agents][Effects of antisecretory therapy on serum gastrin and argyrophil cells of the fundus mucosa]
P50
Q28184858-302E0DF1-01CA-4AA9-81FC-CC9FA0F041B9Q28195695-EEF45FD3-9E02-46F6-90FC-9F6F33A479E7Q28196637-94CC95C2-DB5A-4AE5-95C5-F230F1AF2BD2Q28212868-F50C2FE1-01BB-4A25-8D84-AACAC00AED64Q28212892-F1552D2A-17A6-48E5-9D39-898D50B4331CQ34681063-66900B47-B873-417F-9E5D-A97DCB946E87Q35732845-63036D3D-4E47-4A9F-BCC0-B48B1A3713C0Q36700650-CA5727C6-11AC-4D55-A5CA-ED060ED9F3BEQ38650032-7D3ED878-79D0-4304-812D-C7BC91A501A5Q38730060-653D562A-821B-4686-AE96-E9AA8FAEFEFAQ39645893-24EC11B2-19C6-454E-95B2-F9732C711E1CQ39860343-44F562DF-C42C-4DFD-916A-4ACF7AF8E01CQ40675143-F6100F91-F998-44FF-8951-1CFEEE37D566Q41441593-373C16D6-9D1B-47C8-B98F-CA94B03F8345Q41925341-55E8AF77-0FA8-4610-94B9-FA090DB41D66Q42993489-10D47884-A1EC-49E2-964C-E39F16C61835Q43030321-DCF85DFF-593F-4B71-9D67-D9430BC90139Q43040660-71EB6C7C-7AC8-457C-8EA1-6E8C6B460F73Q43048549-DFBBA8BF-A70C-454F-A84A-A9129F2A7BDFQ43483873-59BD62C1-5B6E-4DB2-AA6F-0A940A71BCE7Q43588273-E853DF87-AB85-4A3B-947C-8CDBDCF4D85AQ43963350-66E69D7A-9015-4616-AB3B-C403E607BCB3Q44008129-134660C4-9BE1-4EA4-9F97-7C0A93027892Q44502070-83AF260A-3FA7-4240-9A51-1D7F6344FF28Q44921126-B47EE2DD-47DC-4D3D-B53B-9A2131A2E345Q44973627-EB86903A-4081-496B-8B7A-3856A360B026Q45418408-295DA8EC-34F6-47A8-A6DA-592C0E2759FDQ45895334-5DBCDAB5-9D3D-4343-A1CC-2E10EF9F0E34Q46138708-8691DAC7-F3F3-4AA4-8BFB-CCAD699E7EEBQ46435995-DEFA2FEC-0AA6-436A-846C-CD5D73A0A29EQ46502311-E6472E42-78F1-4E37-B529-F7F61204D79DQ50579096-0500DDE9-469B-4187-9B31-776BA1BCA0DBQ51031382-955064D8-2C57-48FA-B933-46CB66C9E4CDQ51772779-1E22A5FD-7264-4FF6-A933-6E7AE5F19219Q53511469-17CB21EA-53EB-45A3-98EB-41D55CCDEDE7Q53890794-87FA765B-177D-44C6-B885-2BBB885E4832Q58088649-65381DD4-F446-443E-815D-0E8D65B7863BQ67868296-43F754B7-C7F2-47EB-9BEC-BB60B60D2CA7Q67979617-A04E6922-B39F-4999-82B2-87323362A67FQ68007928-8FFA734C-A825-48BC-AA59-754266FB3EFC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gérard Thiéfin
@ast
Gérard Thiéfin
@en
Gérard Thiéfin
@es
Gérard Thiéfin
@nl
Gérard Thiéfin
@sl
type
label
Gérard Thiéfin
@ast
Gérard Thiéfin
@en
Gérard Thiéfin
@es
Gérard Thiéfin
@nl
Gérard Thiéfin
@sl
prefLabel
Gérard Thiéfin
@ast
Gérard Thiéfin
@en
Gérard Thiéfin
@es
Gérard Thiéfin
@nl
Gérard Thiéfin
@sl
P106
P31
P496
0000-0002-8626-8352